Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations & Strategic Analysis Chris Fenimore - Senior Vice President, Finance & Chief Financial Officer Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay, let's go ahead and get started. Thanks everybody for being here.
REGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Regeneron Pharmaceuticals, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Marion McCourt - EVP, Commercial Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone. Thanks so much for joining us.
Regeneron: The Biotech Stock To Buy Now
Biotech stocks, including Regeneron, have seen significant declines due to regulatory and political uncertainty, presenting a potential buying opportunity as seller exhaustion nears. Regeneron's 40% drop is driven by multiple factors, including Eylea's market share concerns, DOJ lawsuits, and general sector uneasiness. Despite the drop, Regeneron remains a highly profitable company with a robust pipeline, trading at a dirt-cheap valuation and offering long-term growth potential.
Regeneron initiated with a Neutral at Citi
Citi initiated coverage of Regeneron with a Neutral rating and $895 price target. Multiple clinical data readouts should "keep investors engaged" over the next 12-24 months and while Eylea-HD, or high dose, is "off to a good start," standard Eylea headwinds could lead to declining franchise growth, the analyst tells investors.
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron shares fell 9.2% after the Q3 2024 report, making the company's valuation more attractive. The strong report was the 15th of 16 in the last four years to beat expectations. Investors were spooked by slowing sales growth for EYLEA and lack of revenue expectations in 2024 Guidance.
Regeneron: Investors In Panic Mode On Increased Eylea Fears
Shares of Regeneron are in free fall after recent litigation setbacks on Eylea and with Amgen launching a biosimilar low-dose version of Eylea. Investors may be overestimating the negative impact of this development. Dupixent remains in high growth mode with an expanding collaboration profit margin, and Libtayo is also delivering healthy revenue growth.
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - SVP, Finance and CFO Conference Call Participants Taylor Hanley - JPMorgan Tyler Van Buren - TD Cowen Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Terence Flynn - Morgan Stanley Christopher Raymond - Piper Sandler Salveen Richter - Goldman Sachs Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets David Risinger - Leerink Partners William Pickering - Bernstein Cory Kasimov - Evercore ISI Operator Good morning and welcome to the Regeneron Pharmaceuticals' Third Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
